SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU
20/6 14:11
Nirogacestat may become the first EU-approved treatment for desmoid tumors, with the decision expected by Q3 2025....